{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '5.2. Treatment Phase', '1. Comprehensive medical history and physical exam, including weight, medications,', 'blood pressure, heart rate and ECOG performance status assessment (days 1, 30', 'and 60)', '2. Adverse event assessment (days 1, 30 and 60)', '3. Study drug dispensation and collection of unused study drug', '4. CBC with differential (days 1, 30 and 60)', '5. CMP (days 1, 30 and 60)', '6. Serum PSA (day 1)', '7. Testosterone (days 1, 30 and 60)', '8. LH plasma level (days 1, 30 and 60)', '9. TSH (days 30 and 60)', '10. Quality of life questionnaires (FACT-P and SF-36) (day 1)', '11. Exploratory biomarkers (see sections 1.4 and 7.3) (performed on tissue, blood and', 'plasma samples) (Days 1 and 30)', '5.3. End of Study (i.e., day 91 of treatment)', '1. Comprehensive medical history and physical exam, including weight, medications,', 'blood pressure, heart rate and ECOG performance status assessment', '2. Adverse event assessment', '3. Unused study drug collection', '4. Systematic 12-core prostate biopsy AND selective site directed biopsy (3-cores per', 'site)', 'Note: In patients with a baseline detectable nodule (PIRADS >3 and >5mm),', 'MRI/TRUS fusion guided biopsy will be used to obtain the site directed biopsies', '37', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '5. CBC with differential', '6. CMP', '7. Serum PSA', '8. Testosterone', '9. LH plasma level', '10. Exploratory biomarkers (see sections 1.4 and 7.3) (performed on tissue, blood and', 'plasma samples)', '11. Quality of life questionnaires (FACT-P and SF-36)', '5.4. Long Term Follow-up', '1. Adverse event assessment (Days 180, 365, 545 and 730)', '2. Minimum 12-core prostate biopsy (Days 365 and 730)', '3. Serum PSA (Days 180, 365, 545 and 730)', '4. Quality of life questionnaires (FACT-P and SF-36) (Days 180, 365, 545 and 730)', '5.5. Long Term Record Review (at Years 3, 4 and 5, +/- 90 days)', '1. Most recent PSA', '2. Prostate biopsy data (e.g. highest Gleason score, number of involved cores)', '3. Local treatment received (e.g. radiation, surgery)', '38', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '6. Study Calendar: All required treatment and end of study procedures and assessments must be done within 7 days () of the specified', 'study visit date. With the exception of the screening prostate biopsy, screening study procedures and assessments must be done 30 days', 'prior to enrollment. Long-term follow-up procedures and assessments should occur two years following Day 1 (+30 days). Medical records', 'will be reviewed yearly (+/- 90 days) through year five in years 3, 4 and 5.', 'Screening', 'Treatment phase', 'End of Study', 'Long-term follow-uph', 'Record Review', 'Day 1', 'Day 30', 'Day 60', 'Day 91', 'Day 180', 'Day 365', 'Day 545', 'Day 730', 'Year 3, 4, 5', 'Day -30 to -1', '(+7 days)', '(+7 days)', '(+7 days)', '(+7 days)', '(+30 days)', '(+30 days)', '(+30 days)', '(+30 days)', '(+90 days)', 'Informed Consent', 'x', 'History and Physicala', 'x', 'x', 'x', 'x', 'x', 'Adverse Event Assessment', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'Study drug dispensation', 'x', 'x', 'x', 'Unused study drug collection', 'x', 'x', 'x', 'CBCb', 'x', 'x', 'x', 'x', 'CMPb', 'x', 'x', 'x', 'x', 'EKG', 'x', 'Serum PSA', 'x', 'x', 'x', 'x', 'x', 'Testosterone', 'x', 'x', 'x', 'x', 'x', 'LH plasma levelb', 'x', 'x', 'x', 'x', 'TSHC', 'x', 'x', 'Exploratory biomarkersd', 'x', 'x', 'Quality of life questionnaires', 'x', 'x', 'x', 'Systematic 12-core biopsy', 'x', 'Site directed biopsy (3-cores per site)', 'Medical Record Review', 'x', 'a. History and physical assessment will include ECOG performance status and toxicity assessments. Visits will also document medications, blood pressure, height (only at screening visit) and', 'weight, and heart rate. Note: nursing assessment will suffice for the physical assessment.', 'b. CBC = Complete blood count with platelets and differential; CMP = Comprehensive metabolic panel (Sodium, Potassium, Chloride, BUN, Serum Creatinine, Calcium, Total Protein, Albumin, Total', 'Bilirubin, AST, ALT, Alkaline Phosphatase, CO2); LH = Luteinizing hormone; TSH = thyroid stimulating hormone.', 'C. If TSH is abnormal, Free T3 and T4 levels must be checked.', 'd. See sections 1.4 and 7.3 for a description of exploratory biomarkers. These will be performed on tissue, blood and plasma sample. Note: Samples obtained at the Day 1 visit will serve as', 'baseline samples.', 'e. Quality of life questionnaires include the FACT-P and SF-36 questionnaires.', 'f.', 'Screening 12-core biopsy may be performed up to 12-months prior to enrollment.', 'g. In patients with a baseline detectable nodule (PIRADS >3 and >5mm), MRI/TRUS fusion guided biopsy will be used to obtain the site directed biopsies. Otherwise, this will be done using the', 'saved coordinates of known areas of cancer as determined from the screening systematic 12-core biopsy.', 'h. Patients will be required to be seen by a provider or research nurse for long-term follow-up appointments on Day 180, Day 365, Day 545 and Day 730. Long-term follow-up on Year 3, Year 4 and', 'Year 5 are conducted by medical record review only to collect data on most recent PSA, highest gleason score on most recent biopsy and local treatment received (e.g. radiation, surgery).', \"'X' indicates study or exam to be done on the specified day.\", '39', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}